1
|
Truchetet A, Goetz C, Bursztejn AC. Prevalence and comorbidities of dermatoporosis: A French prospective observational study in general medicine consultation. J Eur Acad Dermatol Venereol 2023; 37:e1465-e1467. [PMID: 37471483 DOI: 10.1111/jdv.19366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 07/18/2023] [Indexed: 07/22/2023]
|
2
|
Schneider C, Granel-Brocard F, Seiller H, Bursztejn AC. [Pigmented macules]. Rev Med Interne 2023; 44:321-323. [PMID: 37268329 DOI: 10.1016/j.revmed.2023.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Revised: 12/11/2022] [Accepted: 01/01/2023] [Indexed: 06/04/2023]
|
3
|
Zitouni J, Bursztejn A, Belloni Fortina A, Beauchet A, Di Lernia V, Lesiak A, Thomas J, Topkarci Z, Murashkin N, Brzezinski P, Torres T, Chiriac A, Luca C, Mcpherson T, Akinde M, Maruani A, Epishev R, Vidaurri De La Cruz H, Luna P, Amy De La Breteque M, Lasek A, Bourrat E, Bachelerie M, Mallet S, Steff M, Bellissen A, Neri I, Zafiriou E, Van Den Reek J, Sonkoly E, Kupfer-Bessaguet I, Leducq S, Mahil S, Smith C, Flohr C, Bachelez H, Mahé E. COVID-19 et psoriasis de l’enfant : facteurs associés à une évolution défavorable de la COVID-19 et impact de l’infection sur le psoriasis. Registre Chi-PsoCov. ANNALES DE DERMATOLOGIE ET DE VÉNÉRÉOLOGIE - FMC 2022. [PMCID: PMC9748132 DOI: 10.1016/j.fander.2022.09.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
4
|
Lasek A, Bellon N, Mallet S, Puzenat E, Bursztejn AC, Abasq C, Mazereeuw-Hautier J, Chiaverini C, Hubiche T, Raison Peyron N, Du Thanh A, Barbarot S, Aubert H, Reguiai Z, Droitcourt C, Fievet C, Bellissen A, Bachelerie M, Nosbaum A, Leymarie A, Armingaud P, Masson Regnault M, Mahé E. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicenter retrospective cohort in daily practice. J Eur Acad Dermatol Venereol 2022; 36:2423-2429. [PMID: 35854650 DOI: 10.1111/jdv.18450] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 06/24/2022] [Indexed: 11/27/2022]
Abstract
BACKGROUND Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD). OBJECTIVE The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice. METHODS Patients aged 6 to 11, who had received a first dose of dupilumab were included in this multicenter retrospective cohort study. The primary endpoint was change in SCORAD after 3 months of treatment. Secondary endpoints were change in IGA score at 3 months, proportion of patients with SCORAD50 and SCORAD75, description of adverse events and proportion of children in our cohort who would be excluded from pivotal phase 3 clinical trial. RESULTS 80 patients were included. After 3 months of treatment, there was a significant decrease in SCORAD (mean: 21.8 ± 13.8 vs 53.9 ± 18.5; p<0.0001) and IGA (1.3 ± 0.8 vs 3.5 ± 0.7; p<0.0001). Conjunctivitis was observed in 11.3%(n=9/80); 3 patients experienced dupilumab facial redness (DFR); 17.5% (n=14/80) reported injection site reactions; 6.3% (n=5/80) discontinued treatment. 61.2 % (n=49/80) children were ineligible in the phase 3 trial. LIMITATIONS There is no control group. Because it was a real life study based on information from patient medical records in a French multicenter cohort, we cannot rule out the presence of reporting bias generated by the use of patient reported characteristics and missing information. CONCLUSION These real-life data confirm the efficacy and safety of dupilumab in children with moderate to severe AD extended to dyshidrosis and atopic prurigo but it also revealed a lower frequency of DFR and conjunctivitis. However, administration in injectable form may be a barrier in this age group.
Collapse
|
5
|
Gael M, Adam T, Mariano-Bourin M, Bursztejn AC. Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: A systematic review of current evidence and analysis of response predictors. J Eur Acad Dermatol Venereol 2022; 36:1541-1551. [PMID: 35569006 DOI: 10.1111/jdv.18221] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2021] [Accepted: 04/21/2022] [Indexed: 11/28/2022]
Abstract
Dupilumab has demonstrated a great reduction on chronic pruritus that is the hallmark of atopic dermatitis (AD). Underscoring relevant pathogenesis similarities emerging from AD, chronic idiopathic pruritus (CIP) and chronic prurigo (CP), several authors suggested the beneficial role of dupilumab in these conditions. The evidence on this subject is limited with no precise data available. In this study, we carried out a systematic literature review in order to evaluate the efficacy of dupilumab on both pruritus and skin manifestations in the two largest retrospective cohorts of patients with CP and CIP and tried to identify potential response predictors. Electronic searches were conducted on 4 databases. Our primary outcome was the improvement in pruritus measured by a reduction in patient's reported numerical rating scale of itch (NRSI) by > 4. Secondary outcomes included: proportion of patients with complete response at the end of treatment, reduction in the number of lesions by the Investigator Global Assessment (IGA), improvement in numerical rating scale of sleep (NRSS), improvement in quality of life measured by the Dermatology Life Quality Index (DLQI), time until patient perceived any improvement (Time-First) and time until patient reported absence of pruritus (Time-Final). Descriptive statistics were calculated for each demographic and clinical variable. Univariate logistic regression analyses were conducted to explore association between response to dupilumab and potential predictive factors. We included 25 articles in the analysis, counting a total of 153 patients. Based on CP patients' cohort (n=132), the mean NRSI at baseline was 8.79 ±0.86 and the NRSI final was 2.32 ±1.27. The mean time to first improvement was 5.18 ±3.13 weeks, while the time to complete improvement of pruritus (Time-final) was 13.6 ±12.0 weeks. Ninety patients out of 109 (83%) noticed improvement in pruritus before 4 weeks of dupilumab therapy. At the end of treatment, 18 patients out of 126 (14%) had a complete remission of pruritus and 110 patients out of 123 (89%) had a reduction of NRSI > 4. The reduction in NRSI was significantly greater in patients improving before 4 weeks of treatment (6.57 ±1.71) compared to patients improving in more than 4 weeks (5.49 ±1.39, p<0.001). Patients with history of AD and those who have been previously treated with cyclosporine or methotrexate had a significantly lower reduction in NRSI (e.g. 6.05 ±1.34 vs 7.08 ±1.90 p<0.01 for non-associated AD patients). Based on CIP patient's cohort (n=21), the mean NRSI at baseline was 8.33 ±0.80 and the NRSI final was 0.95 ±0.59. The mean time to first improvement was 2 ±0 weeks, while the time to complete improvement (Time-final) was 14.6 ±10 weeks. At the end of treatment, 3 patients out of 21 (14%) had a complete remission of pruritus and 100% of patients had a reduction of NRSI > 4. No serious treatment-emergent adverse events were reported. The most common adverse event was mild conjunctivitis (13 cases). We highlight the importance of one early sign of improvement as predictor of the future response to dupilumab: the improvement before 4 weeks of treatment that leads significantly to a greater final reduction in NRSI. Furthermore, patients with the presence or history of atopy appear to be less responsive to dupilumab than non-atopic patients and develop more side effects, in particular conjunctivitis.
Collapse
|
6
|
Bursztejn AC, Shourick J, Bodemer C, Lasek A, Mahé E, Merhand S, Sampogna F, Taïeb C, Boralevi F, Ezzedine K, Barbarot S, Mallet S, Abasq C. Feelings of guilt in parents of children with atopic dermatitis. J Eur Acad Dermatol Venereol 2021; 36:e155-e157. [PMID: 34586676 DOI: 10.1111/jdv.17712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 09/17/2021] [Indexed: 11/30/2022]
|
7
|
Moreau E, Rousseau H, Marzouki Zerouali A, Melgar E, Henry J, Schmutz JL, Escobar GF, Bursztejn AC. A study of corticophobia in adult psoriasis patients: a French cross-sectional observational study. J Eur Acad Dermatol Venereol 2021; 35:e768-e770. [PMID: 34062017 DOI: 10.1111/jdv.17435] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2021] [Revised: 05/07/2021] [Accepted: 05/21/2021] [Indexed: 11/28/2022]
|
8
|
Delhomme C, Mariano-Bourin M, Melgar E, Bologna S, Lardenois E, Poreaux C, Granel-Brocard F, Schmutz JL, Bursztejn AC. Mélanome métastatique et lymphome malin non hodgkinien : association rare, diagnostic complexe mais prise en charge commune possible. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Seiller H, Nguyen Thi-Lambert P, Jaussaud R, Bursztejn AC. Traitement par rituximab dans les maladies auto-immunes dermatologiques : étude du risque infectieux. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Moreau E, Rousseau H, Marzouki Zerouali A, Melgar E, Henry J, Schmutz J, Bursztejn A. Étude de la corticophobie chez les patients adultes atteints de psoriasis. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Bonigen J, Chiaverini C, El Hachem M, Leclerc-Mercier S, Rosenthal JM, Bursztejn AC, Hadj-Rabia S, Bodemer C. Les épidermolyses bulleuses jonctionnelles par mutations des intégrines α6β4 : série multicentrique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Colin S, Marzouki-Zerouali A, Evon P, Mariano-Bourin M, Bursztejn AC. Efficacité de l’étanercept dans les toxidermies sévères : 3 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Mahé E, Corgibet F, Maccari F, Hadj-Rabia S, Phan C, Ruer-Mulard M, Boralévi F, Barbarot S, Bursztejn AC, Lahfa M, Severino-Freire M, Aubin F, Barthélémy H, Amy de la Bretêque M, Beauchet A. Prescriptions hors AMM (autorisation de mise sur le marché) dans le psoriasis de l’enfant. Ann Dermatol Venereol 2020; 147:429-438. [DOI: 10.1016/j.annder.2020.01.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 01/03/2020] [Accepted: 01/27/2020] [Indexed: 01/13/2023]
|
14
|
Henry J, Bursztejn AC, Bonhomme A, Cuny JF, Mitcov M, Blanchard-Laumonnier E, Schmutz JL. Épidermolyse bulleuse acquise à type de pemphigoïde de Brunsting-Perry : difficultés diagnostiques et thérapeutiques. Ann Dermatol Venereol 2020; 147:439-445. [DOI: 10.1016/j.annder.2020.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 11/29/2018] [Accepted: 01/17/2020] [Indexed: 11/26/2022]
|
15
|
Melgar E, Escobar GF, Granel-Brocard F, Remen T, Marzouki-Zerouali A, Geoffrois L, Martin H, Schoeffler A, Schmutz JL, Bursztejn AC. Assessment of patient knowledge and completion of advance directives in oncodermatology. Br J Dermatol 2020; 183:972-973. [PMID: 32473026 DOI: 10.1111/bjd.19257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
16
|
Barbé J, Poreaux C, Remen T, Schoeffler A, Cloché V, Schmutz JL, Bursztejn AC. Traitement par dupilumab et complications oculaires chez les patients atteints de dermatite atopique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Barbé J, Bursztejn AC, Schmutz JL. Infection à Rhodococcus equi de localisation inhabituelle, chez l’immunocompétent. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Mahé E, Corgibet F, Phan C, Maccari F, Hadj-Rabia S, Ruer-Mulard M, Boralévi F, Barbarot S, Bursztejn AC, Lahfa M, Severino-Freire M, Aubin F, Barthelemy H, Amy de la Breteque M, Sialiti S, Beauchet A. Prescriptions hors AMM (autorisation de mise sur le marché) dans le psoriasis de l’enfant. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Melgar E, Granel-Brocard F, Marzouki-Zerouali A, Geoffrois L, Muller P, Shoeffler A, Schmutz JL, Bursztejn AC. Acceptabilité et fréquence de rédaction des directives anticipées chez les patients d’onco-dermatologie. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Martin H, Bursztejn A, Albuisson E, Leguern A, Mahe E, Villemur B, Blaise S, Perceau G, Goujon E, Lok C, Modiano P, Debure C, Guillot B, Maillard H, Say M, Carvalho-Lallement P, Dompmartin A, Journet-Tollhupp J, Schmutz JL, Senet P, Schoeffler A. Caractéristiques des plaies chroniques chez les toxicomanes : étude rétrospective de 58 patients. Ann Dermatol Venereol 2019; 146:793-800. [DOI: 10.1016/j.annder.2019.09.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2019] [Revised: 07/07/2019] [Accepted: 09/03/2019] [Indexed: 12/21/2022]
|
21
|
Fleurentin L, Divaret-Chauveau A, Schmutz JL, Bursztejn AC. Évaluation des pratiques parentales en matière de soins d’hygiène et soins locaux dans la dermatite atopique de l’enfant. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Barbé J, Lardenois E, Schmutz JL, Bursztejn AC. Une forme historique de lymphome cutané anaplasique à grandes cellules ALK positif. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Bursztejn A, Magdelaine C, Mortemousque B, Zerah M, Schmutz J, Leheup B. Hypotrichosis with keratosis follicular and hyperostosis: a new phenotype due to
GJA
1
mutation. J Eur Acad Dermatol Venereol 2019; 33:e219-e221. [DOI: 10.1111/jdv.15405] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
24
|
Letournel H, Campagne J, Moulinet T, Corriger J, Mohamed S, Deibener-Kaminsky J, Bursztejn A, Jaussaud R. Mastocytose cutanée ou systémique indolente associée à des manifestations auto-immunes : Étude sur 40 cas. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Moawad S, Reigneau M, de la Fouchardière A, Soufir N, Schmutz JL, Granel-Brocard F, Phan A, Bursztejn AC. Clinical, dermoscopic, histological and molecular analysis of BAP1-inactivated melanocytic naevus/tumour in two familial cases of BAP1 syndrome. Br J Dermatol 2018; 179:973-975. [DOI: 10.1111/bjd.16740] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Fatrez B, Charbit L, Moawad S, Brault F, Freling E, Schmutz JL, Bursztejn AC. Méningo-encéphalite herpétique compliquant un DRESS. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Cales S, Beauchesne P, Schmutz J, Bursztejn A. Tumeurs malignes et neurofibromatose de type 1 : étude rétrospective dans un centre de compétence. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.419] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Fener M, Charbit L, Fréling E, Bursztejn AC, Schmutz JL. Lupus érythémateux cutané subaigu associé à des paraffinomes mammaires. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Fener M, Bursztejn AC, Schmutz JL. Perception de l’évolution de la qualité du sommeil depuis l’introduction d’une biothérapie chez des patients atteints de psoriasis. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
30
|
Babic V, Petitpain N, Guy C, Trechot P, Bursztejn A, Faillie JL, Vial T, Schmutz J. Ulcérations induites par le nicorandil : une étude observationnelle de tous les cas rapportés à la Banque nationale de pharmacovigilance pendant 10 ans. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
Rouyer L, Moawad S, Charbit L, Freling E, Bursztejn A, Schmutz JL. Syndrome de Stevens-Johnson-radiation recall secondaire au nivolumab. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Bursztejn AC, Goffinet L, Mitcov M, Cribier B, Lipsker D. Un caleçon engainant. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Bursztejn AC, Baumann M, Lipsker D. Ehlers-Danlos syndrome related to FKBP14 mutations: detailed cutaneous phenotype. Clin Exp Dermatol 2016; 42:64-67. [PMID: 27905128 DOI: 10.1111/ced.12983] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/14/2016] [Indexed: 11/28/2022]
Abstract
In 2012, a new Ehlers-Danlos (ED) variant, characterized by severe progressive kyphoscoliosis, neonatal myopathy and hearing loss, with normal urinary lysylpyridinoline to hydroxylysylpyridinoline ratio and most often a recurrent homozygous mutation in the FKBP14 gene, was reported. Because one of the major affected tissues in ED syndrome is the skin, recognition of the cutaneous features of this newly recognized EDS variant is important. We describe the cutaneous phenotype of an adolescent girl harbouring the recurrent homozygous FKBP14 mutation. Distinctive features included molluscoid pseudotumours and multiple isolated comedones. Molluscoid pseudotumours are a characteristic finding in patients with the classic ED variant, but are rarely reported in other variants. We discuss the cutaneous phenotype of FKBP14-deficient EDS and compare it with other kyphoscoliotic variants.
Collapse
|
34
|
Charbit L, Bursztejn AC, Mohamed S, Kaminsky P, Lerondeau B, Barbaud A, Deibener-Kaminsky J, Schmutz JL. Nécroses digitales étendues au cours d’une dermatomyosite avec anticorps anti-MDA-5. Ann Dermatol Venereol 2016; 143:537-42. [DOI: 10.1016/j.annder.2016.03.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Revised: 02/07/2016] [Accepted: 03/10/2016] [Indexed: 01/09/2023]
|
35
|
Charbit L, Mahé E, Phan A, Chiaverini C, Boralevi F, Bourrat E, Lasek A, Maruani A, Aubin F, Droitcourt C, Barbarot S, Mallet S, Mazereeuw-Hautier J, Begon E, Abasq C, Plantin P, Souillet AL, Hadj-Rabia S, Bursztejn AC. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol 2016; 174:1118-21. [DOI: 10.1111/bjd.14326] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
36
|
Mahé E, Boralevi F, Lenormand C, Bursztejn AC, Estève E, Phan A, Bourrat E, Lacour JP, Richard MA, Acher A, Bénéton N, Descamps V, Bodemer C, Lagaude M, Sigal ML, Jullien D. Psoriasis segmentaire : aspects cliniques et thérapeutiques. Une étude nationale de 27 observations. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
37
|
Larquey M, Bursztejn A, Reigneau M, Barbaud A, Schmutz J. Xeroderma pigmentosum de type C : un nouveau cas français autochtone. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Amode R, Hadj-Rabia S, Bursztejn AC, Phan A, Boralevi F, Droitcourt C, Mazereeuw-Hautier J, Piram M, Plantin P, Absaq C, Lasek-Duriez A, Balguierie X, Maruani A, Beauchet A, Mahé E. Palmoplantar psoriasis, a frequent and severe clinical type of psoriasis in children. J Eur Acad Dermatol Venereol 2015; 30:1390-2. [DOI: 10.1111/jdv.13236] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
39
|
Babic V, Bursztejn AC, Moulinet T, Deibener-Kaminski J, Freling E, Lerondeau B, Reigneau M, Schmutz JL, Cuny JF. Syndrome de Sharp sévère ou dermatomyosite à anticorps MDA5 ? Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Bursztejn AC, Nemos C, Gastin I, Trechot P, Barbaud A. Étude CNV pangénomique chez 18 patients DRESS : deux nouveaux gènes candidats. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
41
|
Amode R, Hadj-Rabia S, Phan A, Bursztejn AC, Ferneiny M, Boralevi F, Souillet AL, Chiaverini C, Bourrat E, Miquel J, Vabres P, Barbarot S, Bessis D, Mahe E. Psoriasis palmoplantaire : forme clinique fréquente et sévère de psoriasis chez l’enfant. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Boralevi F, Miquel J, Bursztejn AC, Mahé E, Chiaverini C, Laumaillé-Cadiou C, Buzenet C, Bourrat E, Kubica E, Ezzedine K. Tolérance de l’ivermectine chez le nourrisson et l’enfant de moins de 15 kg : observatoire multicentrique. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
43
|
Deheb Z, Schmutz JL, Bursztejn AC, Poreaux C, Barbaud A. À propos d’un cas : réaction paradoxale sous ustékinumab. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Charbit L, Mahe E, Phan A, Droitcourt C, Boralevi F, Puzenat E, Abasq C, Aubert H, Barbarot S, Avenel-Audran M, Rodriguez L, Begon E, Mallet S, Balguerie X, Aubin F, Piram M, Souillet AL, Maruani A, Plantin P, Bourrat E, Lacour JP, Chiaverini C, Mazereeuw-Hautier J, Labreze C, Lasek A, Fleuret C, Kupfer I, Hadj-Rabia S, Bursztejn AC. Traitements systémiques du psoriasis de l’enfant : étude multicentrique nationale chez 140 enfants. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
45
|
de Vitry A, Bursztejn AC, Speyer E, Barbaud A, Schmutz JL. Étude comparative des traitements par bolus de méthylprédnisolone et photothérapie dans la pelade. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
46
|
Reigneau M, Granel-Brocard F, Geoffrois L, Poreaux C, Peiffert D, Cuny JF, Bursztejn AC, Waton J, Schmutz JL, Barbaud A. Apport d’une consultation de dermatologie d’urgence dans un centre de lutte contre le cancer français. Ann Dermatol Venereol 2014; 141:375-8. [DOI: 10.1016/j.annder.2014.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2013] [Revised: 01/01/2014] [Accepted: 03/03/2014] [Indexed: 11/30/2022]
|
47
|
Chiaverini C, Charlesworth A, Fernandez A, Barbarot S, Bessis D, Bodemer C, Bursztejn AC, Cobo AM, Del Rio M, D'Incan M, Labrèze C, Langlet C, Mazereeuw J, Miquel J, Vabres P, Meneguzzi G, Lacour JP. Aplasia cutis congenita with dystrophic epidermolysis bullosa: clinical and mutational study. Br J Dermatol 2014; 170:901-6. [DOI: 10.1111/bjd.12741] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/14/2013] [Indexed: 12/11/2022]
|
48
|
Bursztejn AC, Bonneau D, Soufir N, Leheup B, Martin L. Syndrome de Woodhouse-Sakati : des signes dermatologiques méconnus ? Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
49
|
Bursztejn AC, Jonard L, Cribier B, Barbaud A, Martin-Coignard D, Schmutz JL. Syndrome H : premier cas français. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
50
|
Leclerc-Mercier S, Bodemer C, Furio L, Hadj-Rabia S, Weibel L, Bursztejn AC, Bourrat E, Ortonne N, Hovnanian A, Fraitag S. Première étude rapportant les aspects histologiques du syndrome de Netherton : une série de 63 patients. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|